Skin Transcriptional Profiles In Psoriatic Patients Under Adalimumab Biotherapy
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
The expertise in the characterization of transcriptomics profile in lesional psoriatic skin and on the availability of innovative therapy for these patients.The investigators propose to follow the modification of the skin transcriptomics profile in psoriatic patients during successful Adalimumab biotherapy. Skin transcriptomics profiles of normal skin, psoriatic non lesional skin, and psoriatic lesional skin before and after biotherapy will be compared. The investigators will focus on the modification of the cytokine "signature" in these skin lesions and of some markers of keratinocyte inflammation. The modification of the transcriptomics profile induced by the biotherapy will be correlated to the clinical response Psoriasis Area and Severity Index.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years to 99 Years (Adult, Older Adult)
Sexes Eligible for Study:
Patients with chronic plaque psoriasis involving at least 10% of body surface area with no previous biotherapy.
Adalimumab prescribed in usual practice
Patients presenting a contraindication to the use of Adalimumab:
hypersensibility in Adalimumab or in one of the excipients.
Patients presenting an evolutionary tuberculosis or the other severe infections such as sepsis and opportunist infections
presenting patients one cardiac insufficiencies moderated in severe
Patients under anakinra or abatacept
current participation in another study of clinical research